Cipher Pharmaceuticals Company Profile (NASDAQ:CPHR)

Analyst Ratings

Consensus Ratings for Cipher Pharmaceuticals (NASDAQ:CPHR) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.20 (22.53% upside)

Analysts' Ratings History for Cipher Pharmaceuticals (NASDAQ:CPHR)
Show:
DateFirmActionRatingPrice TargetActions
4/13/2016TD SecuritiesInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/18/2016GMP SecuritiesInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/30/2015CIBCInitiated CoverageSector Outperform -> Outperform$6.20View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Cipher Pharmaceuticals (NASDAQ:CPHR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/4/2015$0.07($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2015$0.02$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115$0.17$0.10$7.88 million$9.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015$0.12$0.12ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cipher Pharmaceuticals (NASDAQ:CPHR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.02)($0.02)($0.02)
Q3 20161($0.01)($0.01)($0.01)
Q4 20161($0.03)($0.03)($0.03)
Q1 20171$0.08$0.08$0.08
Q2 20171$0.06$0.06$0.06
Q3 20171$0.05$0.05$0.05
Q4 20171$0.05$0.05$0.05
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cipher Pharmaceuticals (NASDAQ:CPHR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cipher Pharmaceuticals (NASDAQ:CPHR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Cipher Pharmaceuticals (NASDAQ:CPHR)
DateHeadline
07/20/16 11:00 AMNotice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call - [CNW Group] - Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call
07/14/16 07:31 AMTrading Report: Manufacturing Stocks Gainers, Losers
07/09/16 04:59 AMManufacturing Stocks Weekend Recap
07/06/16 09:00 AMSpecial Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited - [CNW Group] - Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited
06/21/16 08:06 AMManufacturing Stocks Gainers and Losers
06/21/16 08:06 AMEdesa Biotech licenses skin disorder treatment from Cipher
05/31/16 09:00 AMCipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences - [CNW Group] - Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences
05/30/16 01:30 PMCipher Pharmaceuticals Inc. (CPHR) Broker Price Targets For The Coming Week - Share Trading News - Cipher Pharmaceuticals Inc. (CPHR) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Cipher Pharmaceuticals Inc. (CPHR). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...
05/27/16 12:36 PMCipher Pharmaceuticals Inc. (CPHR) Updated Price Targets - FTSE News - Cipher Pharmaceuticals Inc. (CPHR) Updated Price TargetsFTSE NewsCipher Pharmaceuticals Inc. has a 50 day moving average of 5.93 and a 200 day moving average of 4.80. The stock's market capitalization is 150.98M, it has a 52-week low of 3.55 and a 52-week high of 10.25. The share price of the company (CPHR) was up ...
05/19/16 10:54 AMBroker Roundup For Cipher Pharmaceuticals Inc. (CPHR) - Share Trading News - Broker Roundup For Cipher Pharmaceuticals Inc. (CPHR)Share Trading NewsThey now have a USD 6.2 price target on the stock. The share price of Cipher Pharmaceuticals Inc. (CPHR) was down -1.67% during the last trading session, with a day high of 6.00. 868 shares were traded on Cipher Pharmaceuticals Inc.'s last session.
05/19/16 10:54 AMPrice Advance – ATRM, CPHR, GBR, CCXI, TCX, PFNX, NVFY - Cipher Pharmaceuticals Inc (CPHR) traded at $11.50 + 1.42 (14.03 pct). The company is -5.76 pct in the last four weeks, -18.79 pct year-to-date, and +56.00 pct during the past four quarters. New Concept Energy Inc (GBR) traded at $2.19 + 0.29 (15.26 pct).
05/16/16 10:12 AMNext Weeks Broker Price Targets For Cipher Pharmaceuticals Inc. (CPHR) - Share Trading News - Next Weeks Broker Price Targets For Cipher Pharmaceuticals Inc. (CPHR)Share Trading NewsCipher Pharmaceuticals Inc. has a 50 day moving average of 5.70 and a 200 day moving average of 4.71. The stock's market capitalization is 156.74M, it has a 52-week low of 3.55 and a 52-week high of 11.65. The share price of the company (CPHR) was up ...
05/11/16 10:29 AMCipher Pharmaceuticals Ltd. :CPHR-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/05/16 09:56 AMCalgary indie pop act Lab Coast ready to deliver on all expectations - MISSISSAUGA, Ont. - MISSISSAUGA, Ontario (AP) _ Cipher Pharmaceuticals Inc. (CPHR) on Thursday reported a first-quarter loss of $2.7 million, after reporting a profit in the same period a year earlier... Where's the beef? Earls restaurants says it's back ...
05/05/16 09:56 AMCipher Pharmaceuticals posts first-quarter loss of $2.7 million - MISSISSAUGA, Ont. - MISSISSAUGA, Ontario (AP) _ Cipher Pharmaceuticals Inc. (CPHR) on Thursday reported a first-quarter loss of $2.7 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Mississauga, Ontario-based ...
05/03/16 09:44 AMCipher Pharma (CPHR) Licenses Global Rights to Dalhousie University's Investigational Tattoo Removal Cream - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Cipher Pharmaceuticals Inc. (NASDAQ: CPHR) announced it has licensed the worldwide rights to develop and commercialize an investigational tattoo removal cream being ...
05/02/16 10:37 AMCipher Pharma (CPHR) Licenses Global Rights to Dalhousie University's Investigational Tattoo Removal Cream - StreetInsider.com - Cipher Pharma (CPHR) Licenses Global Rights to Dalhousie University's Investigational Tattoo Removal CreamStreetInsider.comCipher Pharmaceuticals Inc. (NASDAQ: CPHR) announced it has licensed the worldwide rights to develop and commercialize an investigational tattoo removal cream being developed at Dalhousie University in Halifax, Nova Scotia by Alec Falkenham, a PhD ...Cipher acquires global rights to tattoo removal creamSeeking Alphaall 2 news articles »
04/24/16 09:28 AMCipher Pharmaceuticals Inc. (NASDAQ:CPHR) Has An Average Rating Of 4 - Investor Newswire - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) Has An Average Rating Of 4Investor NewswireAlpha One uses algorithm-based analytics to know about a stock sentiment varying as per the published content on online channels. In this analysis, the group considers only the most relevant news sources on a daily basis. Cipher Pharmaceuticals Inc.and more »
04/24/16 09:28 AMAfter Last Week What Do Analysts Think Of Cipher Pharmaceuticals Inc. (CPHR) - Share Trading News - After Last Week What Do Analysts Think Of Cipher Pharmaceuticals Inc. (CPHR)Share Trading NewsThey now have a USD 6.2 price target on the stock. The share price of Cipher Pharmaceuticals Inc. (CPHR) was down -4.59% during the last trading session, with a day high of 6.13. 5524 shares were traded on Cipher Pharmaceuticals Inc.'s last session.
04/24/16 09:28 AMCipher Pharma's (CPHR) CFO Norm Evans to Retire - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Cipher Pharmaceuticals Inc. (NASDAQ: CPHR) today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in his ...
04/23/16 09:38 AMCipher Pharma's (CPHR) CFO Norm Evans to Retire - StreetInsider.com - Cipher Pharma's (CPHR) CFO Norm Evans to RetireStreetInsider.comCipher Pharmaceuticals Inc. (NASDAQ: CPHR) today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in his current role to ensure a smooth transition of responsibilities, and the Company has ...Analyst Review: Cipher Pharmaceuticals Inc. (CPHR)Risers & FallersCipher Pharmaceuticals Says CFO Evans to Retire; Shares Edge Up (NASDAQ:CPHR)Sonoran Weekly ReviewCipher Pharmaceuticals Inc's Stock Formed A Several Months Bearish Ascending TriangleThe Postall 5 news articles »
04/22/16 10:30 AMAnalyst Review: Cipher Pharmaceuticals Inc. (CPHR) - Risers & Fallers - Analyst Review: Cipher Pharmaceuticals Inc. (CPHR)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Cipher Pharmaceuticals Inc. (CPHR). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 analysts ...Cipher Pharma's (CPHR) CFO Norm Evans to RetireStreetInsider.comCipher Pharmaceuticals Inc's Stock Formed A Several Months Bearish Ascending TriangleThe Postall 3 news articles »
04/16/16 09:33 AMAnalyst Coverage: Cipher Pharmaceuticals Inc. (CPHR) - Risers & Fallers - Mas Market NewsAnalyst Coverage: Cipher Pharmaceuticals Inc. (CPHR)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Cipher Pharmaceuticals Inc. (CPHR). The latest broker reports which are currently outstanding on Friday 15th of April state 0 analysts have a rating of “strong buy”, 0 ...Cipher Pharmaceuticals Inc. (CPHR) Now Covered by TD SecuritiesMas Market NewsCipher Pharmaceuticals Inc. (NASDAQ:CPHR) 50-Day Moving Average At $4.95Markets Dailyall 5 news articles »
04/16/16 09:33 AMCipher Pharmaceuticals Incorporated (NASDAQ:CPHR) Shorted Shares Decreased By 0.25% - Clinton Financial - Cipher Pharmaceuticals Incorporated (NASDAQ:CPHR) Shorted Shares Decreased By 0.25%Clinton FinancialThe short interest to Cipher Pharmaceuticals Incorporated's float is 0.75%. The stock decreased 1.61% or $0.1 on April 15, hitting $6.1. About 5,095 shares traded hands. Cipher Pharmaceuticals Inc (NASDAQ:CPHR) has risen 21.51% since September 10, ...and more »
04/15/16 09:51 AMCipher Pharmaceuticals Inc. (CPHR) Updated Broker Price Targets - Share Trading News - Cipher Pharmaceuticals Inc. (CPHR) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Cipher Pharmaceuticals Inc. (CPHR). The latest reports which are currently in issue on Friday 15th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
04/13/16 09:48 AMCipher Pharmaceuticals Inc. (CPHR) Coverage Initiated by Analysts at TD Securities - Washington News Wire - Washington News WireCipher Pharmaceuticals Inc. (CPHR) Coverage Initiated by Analysts at TD SecuritiesWashington News WireCipher Pharmaceuticals logo Equities research analysts at TD Securities assumed coverage on shares of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) in a report issued on Wednesday, The Fly reports. The brokerage set a “buy” rating on the stock.Hot Alert: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Cipher Pharmaceuticals Inc. (NASDAQ:CPHR ...Stock Transcriptall 2 news articles »
04/13/16 08:07 AMCoverage initiated on Cipher Pharma by TD Securities -
04/12/16 09:22 AMCould Cipher Pharmaceuticals Inc See a Reversal After Having Formed Several Months Ascending Triangle Chart ... - Stock Caller - Could Cipher Pharmaceuticals Inc See a Reversal After Having Formed Several Months Ascending Triangle Chart ...Stock CallerThe stock of Cipher Pharmaceuticals Inc (CPHR) formed an ascending triangle with $4.98 target or 14.00% below today's $5.79 share price. The 8 months triangle pattern indicates high risk for the $153.57M company. If the $4.98 price target is reached ...and more »
04/07/16 09:27 AMCipher Pharma's (CPHR) Dermadexin and Pruridexin Approved in Canada - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR) announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and Pruridexin). Both products were approved in Canada by the Natural and Non-Prescription Health Products ...
02/23/16 07:53 AMCipher Pharma (CPHR) Launches Actikerall in Canada - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR) announced the Canadian launch of Actikerall™ (0.5% fluorouracil and 10% salicylic acid), indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I ...
02/18/16 07:51 AMCipher Pharma (CPHR) Sitavig NDA Accepted for Review by Health Canada - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR) announced that its New Drug Submission for Sitavig™ has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis (cold ...
02/16/16 06:02 AM7:02 am Cipher Pharma announces review acceptance by Health Canada for Sitavig -
02/04/16 12:30 PMStoneCastle's Bruce Campbell Interviewed by The Life Sciences Report - [Marketwired] - Canada is a wellspring for natural resources and the industries built around them. But the country also encompasses healthcare-related businesses that are growing, generating cash flow and flourishing. ...
01/23/16 04:22 PMCipher Pharmaceuticals Inc. (CPHR) - Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical dermatology company in the United States. The company offers CIP-ISOTRETINOIN, a formulation for the treatment of acne; CIP-FENOFIBRATE, a patented formulation of the active ingredient ...
01/15/16 08:00 AMEuro Pacific Canada's Doug Loe Interviewed by The Life Sciences Report - [Marketwired] - The new year is off to a turbulent start, with indices across all markets, including biotech, sliding downward in the face of headwinds from China. Canadian healthcare stocks offer a windbreak for biotech ...
12/21/15 08:45 AMSanta Brings FDA and Health Canada Approvals for New Dermatology Products - [Accesswire] - REDONDO BEACH, CA / ACCESSWIRE / December 21, 2015 / Regulatory approval of products is what pharmaceutical companies wish for as they spend years developing their products. For Oculus Innovative Sciences ...
10/21/15 07:30 AMNotice of Cipher Pharmaceuticals Inc. Q3 2015 Conference Call - [CNW Group] - Notice of Cipher Pharmaceuticals Inc. Q3 2015 Conference Call
10/05/15 06:00 AMCipher announces settlement in patent litigation for Absorica® - [CNW Group] - Cipher announces settlement in patent litigation for Absorica®
08/21/15 10:25 AMCPHR: Product Sales Picked Up Steam in Second Quarter of 2015 -

Social

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CPHR
  • CUSIP:
Key Metrics:
  • Previous Close: $5.06
  • 50 Day Moving Average: $5.33
  • 200 Day Moving Average: $5.10
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $132.41M
  • Beta: 1.83
  • Current Year EPS Consensus Estimate: $-0.15 EPS
  • Next Year EPS Consensus Estimate: $0.11 EPS
Additional Links:
Cipher Pharmaceuticals (NASDAQ:CPHR) Chart for Monday, July, 25, 2016